Pune Magazine

DelveInsight, a leading market research and business consulting firm specializing in life sciences, has published its latest report, “Meningioma Market Insights, Epidemiology, and Market Forecast – 2036.” The report provides a comprehensive analysis of the Meningioma Market Size, Meningioma Epidemiology, current treatment landscape, Meningioma Pipeline, emerging therapies, competitive intelligence, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan (7MM).

Keen to know how the Meningioma Market will evolve by 2036? Request our sample page athttps://www.delveinsight.com/sample-request/meningioma-market

Key Takeaways from the Meningioma Market

• The Meningioma Market Size across the seven major markets (7MM) is expected to witness steady growth during the forecast period (2022–2036), driven by increasing diagnosed cases, improved neuroimaging capabilities, rising incidence of recurrent and high-grade tumors, and expanding research into targeted and investigational therapies.

• According to DelveInsight’s analysis, the Meningioma Market is projected to increase from an indicative market value of 10 in 2022 to 16 by 2036, reflecting the growing demand for effective treatment options and continued innovation in neuro-oncology.

• The United States is expected to account for the largest Meningioma Market among the seven major markets owing to its large diagnosed patient pool, advanced healthcare infrastructure, and increasing adoption of innovative treatment approaches.

• Epidemiological findings indicate that the prevalence of meningioma in the United States is 97.5 per 100,000 individuals. Spinal meningiomas account for 30.7%–38.8% of all primary intradural spinal tumors among adults aged 20 years and above, with nearly 80.3% of cases occurring in females.

• In the United Kingdom, approximately 27% of all brain tumors diagnosed between 1995 and 2017 were meningiomas, making it the most common benign brain tumor diagnosed in the country.

• In Germany, nearly 70% of patients are diagnosed with WHO Grade I meningioma, while 28% and 3% present with Grade II and Grade III disease, respectively. The overall ten-year observed survival is 72%, while relative survival reaches 91%.

• In Japan, meningioma accounts for approximately 17.7% of all diagnosed primary brain tumors, highlighting its significant contribution to the country’s neuro-oncology burden.

• Histologically confirmed meningiomas account for 37.6% of all primary central nervous system (CNS) tumors and 50% of all benign primary CNS tumors. Disease recurrence remains a major challenge, particularly among higher-grade tumors, where recurrence rates may reach 50%–94% in WHO Grade III meningioma.

• Emerging Meningioma Companies, including NeOnc Technologies Holdings, are advancing innovative therapies to address the significant unmet needs in recurrent and high-grade disease. NEO100 is currently being investigated in Phase II clinical development for meningioma.

Key Factors Driving the Meningioma MarketIncreasing Diagnosed Patient Population and Disease Burden

Growing awareness, improved healthcare access, an aging population, and widespread use of advanced neuroimaging techniques are contributing to higher diagnosis rates of meningioma. Earlier detection and improved survivMeningioma Competitive Landscape

The Meningioma Market is gradually evolving as research efforts increasingly focus on developing targeted therapies for patients with recurrent, unresectable, and high-grade disease. While surgery and radiotherapy remain the primary treatment options, there are currently no FDA- or EMA-approved systemic disease-modifying therapies specifically indicated for meningioma, creating significant opportunities for innovation within the Meningioma Treatment Market.

Across the 7MM, several biotechnology companies are advancing novel therapeutic strategies to improve treatment outcomes and address the substantial unmet needs associated with recurrent meningioma. Among the emerging therapies, NEO100 developed by NeOnc Technologies Holdings represents one of the leading investigational candidates currently progressing through clinical development.

NEO100 is a proprietary formulation of Perillyl Alcohol (POH) designed to target central nervous system tumors through innovative delivery approaches. The therapy is being investigated for its potential to regulate neurological pathways involved in tumor growth while utilizing intranasal administration to bypass the blood-brain barrier (BBB), thereby improving drug delivery directly to the brain. Additionally, intra-arterial delivery is designed to create a temporary opening of the BBB, enabling larger therapeutic molecules to reach intracranial tumors more effectively.

Discover more about therapies expected to reshape the Meningioma Treatment Market and gain significant market share @ Meningioma Treatment Landscape

Recent Developments in the Meningioma Market

• In August 2024, NeOnc Technologies Holdings announced the initiation of patient enrollment for its Phase II clinical trial evaluating NEO100-02 in patients with meningioma. The study represents the company’s second concurrent Phase II clinical program for its lead CNS oncology candidate.

• NEO100 continues to be developed under an active Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) and has received both Orphan Drug Designation (ODD) and Fast Track Designation (FTD), supporting its clinical development for patients with meningioma.

• According to DelveInsight’s assessment, increasing research into biomarker-driven therapies, molecular targets, and innovative CNS drug delivery technologies is expected to transform the future Meningioma Pipeline and expand therapeutic opportunities for patients with recurrent and aggressive disease.

What is Meningioma?

Meningioma is a generally slow-growing, predominantly benign tumor that develops from the meninges, the membranous layers surrounding the brain and spinal cord. It is the most common primary intracranial tumor in adults. Although many meningiomas remain asymptomatic and are detected incidentally, symptomatic tumors may cause headaches, seizures, visual disturbances, focal neurological deficits, and cognitive impairment depending on their size and anatomical location.

The World Health Organization (WHO) classifies meningiomas into Grade I (benign), Grade II (atypical), and Grade III (anaplastic/malignant) based on histopathological characteristics. While the majority of tumors are benign, higher-grade meningiomas demonstrate aggressive behavior, increased recurrence rates, and poorer clinical outcomes. Current management primarily consists of maximal safe surgical resection followed by radiotherapy when indicated. However, no universally effective systemic therapy currently exists for recurrent or high-grade disease, highlighting the need for innovative therapeutic approaches.

Meningioma Epidemiology Segmentation

The Meningioma Epidemiology section of the report provides historical and forecasted patient population insights across the seven major markets during the study period 2022–2036. The report analyzes:

• Total Prevalent Cases of Meningioma

• Total Diagnosed Prevalent Cases of Meningioma

• Gender-specific Diagnosed Prevalent Cases of Meningioma

• Severity-specific Diagnosed Prevalent Cases of Meningioma

• Treated Cases of Meningioma

Scope of the Meningioma Market Report

• Therapeutic Assessment: Current and Emerging Meningioma Therapies

• Meningioma Market Dynamics: Market Forecast, Key Assumptions, Emerging Drugs, and Future Market Outlook

• Key Company: NeOnc Technologies Holdings

• Key Therapy: NEO100

• Competitive Intelligence: SWOT Analysis, Conjoint Analysis, Market Access, Pricing Trends, and Reimbursement Assessment

• Unmet Needs, KOL Perspectives, Analyst Views, and Market Opportunities

To know more about companies developing innovative Meningioma therapies, visit @ Meningioma Companies and Clinical Trials

Table of Contents

• Meningioma Market Report Introduction

• Executive Summary of Meningioma

• SWOT Analysis of Meningioma

• Meningioma Patient Share (%) Overview at a Glance

• Meningioma Market Overview at a Glance

• Meningioma Disease Background and Overview

• Meningioma Epidemiology and Patient Population

• Country-specific Patient Population of Meningioma

• Current Treatment Landscape and Medical Practices

• Meningioma Unmet Needs

• Emerging Therapies for Meningioma

• Meningioma Market Outlook

• Country-wise Meningioma Market Analysis (2022–2036)

• Market Access and Reimbursement

• Meningioma Market Drivers

• Meningioma Market Barriers

• Appendix

• Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/